Faculty – 2nd Biosimilar Market Access Strategies Summit

Joanna Brougher
Adjunct Professor, CORNELL LAW SCHOOL

Jay Brown
Senior Director, Outpatient Pharmacy Support Services, NOVANT HEALTH

Divya Chadha Manek
Head, Business Development, NIHR

view speaker profile

Divya has worked for the NIHR CRN for the past nine years. She has hands experience of delivering clinical research from both a site-level and national perspective.

Divya’s current role is to maintain strategic relationships with global and UK life sciences companies. Within this role, Divya provides advice and works collaboratively with companies to optimize how companies utilize government-funded support services to ensure clinical studies are set up quickly and efficiently and recruit to time and target.

Divya also leads on keeping the NIHR CRN abreast of study delivery innovations. In doing so she helps to ensure that the services we provide continually evolve meet the needs of the life sciences industry.

Divya has a degree in Clinical Psychology, a Masters in Clinical Research and is currently undertaking a Ph.D. in Dementia Care.

Dr. Niraj Chhaya
Risk Management, Biosimilars, BOEHRINGER INGELHEIM

Mona Chitre
Vice President of Pharmacy, EXCELLUS BLUECROSS

Christopher Colburn
Director Federal Accounts — Biosimilar Products, PFIZER INCORPORATED

Joseph P. Fuhr, Ph.D.
Adjunct Faculty College of Population Health and Professor Emeritus Economics, WIDENER UNIVERSITY

view speaker profile

Dr. Joseph P. Fuhr, Jr. is a lecturer at College of Population Health Thomas Jefferson University and retired professor of economics at Widener University. He currently serves as a senior fellow with The American Consumer Institute and Ambassador for the Internet Innovation Alliance. Dr. Fuhr received his M.A. and Ph.D. from Temple University and his B.A. from LaSalle University. His primary research areas are antitrust, health economics, pharmacoeconomics, telecommunications and sports economics. In healthcare, he has written on ACOs, hospital mergers, specialty hospitals, exclusive arrangements, health insurance, bundling and doctor’s fees. In pharmacoeconomics, he has written on cost benefit analysis, biosimilars and predictive modeling. He has published more than 60 journal articles, of which 10 are on biosimilars. Professor Fuhr has been an expert witness on numerous cases and has worked on various consulting projects.

Aaron Hakim

view speaker profile

Aaron graduated summa cum laude and Phi Beta Kappa from Yale University with an M.S. in Molecular, Cellular and Developmental Biology and a B.S. in Economics and Molecular Biology. His Master’s thesis was published in and featured on the cover of the Journal of Biological Chemistry, and his more recent work has appeared in JAMA and JAMA Internal Medicine. His research interests include the costs, availability, and use of prescription drugs in the United States. Aaron is currently a third-year MD student at the Yale School of Medicine. Prior to medical school, Aaron was an Associate at a life sciences investment fund in Greenwich, CT.

Nacer Hedroug
Associate Director Validation and Tech Transfer, WOCKHARDT LTD.

Rob Jacobson
Executive Director, AMGEN

Ruediger Jankowsky
Managing Director, CINFA BIOTECH

Bruce A. Leicher
Sr. Vice President and General Counsel, MOMENTA PHARMACEUTICALS, INC.

view speaker profile

Mr. Leicher is Senior Vice President and General Counsel at Momenta Pharmaceuticals Inc., an innovator biotechnology company engaged in the development of complex generic products, biosimilars, interchangeable biologics and novel products. Mr. Leicher has advised biotechnology companies for over 25 years. Mr. Leicher is a frequent lecturer on biotechnology law. Mr. Leicher is also Chair of the Board of the Biosimilars Council, a Division of the Association for Accessible Medicines (AAM). Before joining Momenta, he served in senior legal positions at Altus Pharmaceuticals Inc., Antigenics Inc., Millennium Pharmaceuticals, Inc., Curis, Inc., Genetics Institute, Inc., and Wyeth. In private practice, he served as the Co-Chair of the Life Sciences Practice Group at Hill and Barlow, was an attorney at Hale and Dorr and Butler & Binion, and served as a law clerk to the Honorable Thomas F. Hogan in the U.S. District Court for the District of Columbia after receiving his J.D. from Georgetown University Law Center and his B.A. from the University of Rochester.

Sarfaraz Niazi, Ph.D.
Adjunct Professor, Department of Biopharmaceutical Sciences, UNIVERSITY OF ILLINOIS AT CHICAGO, COLLEGE OF PHARMACY

view speaker profile

Sarfaraz K. Niazi, Ph.D., Adjunct Professor, University of Illinois is the founder of Adello Biologics, a fully integrated biosimilar products company and a consultant to pharmaceutical and biotechnology industry as Founding Chairman of Pharmaceutical Scientist Inc. He has written over 100 research papers, over 60 books and owns over 120 patents in bioprocessing and other technologies and drug discovery. He has 20+ years of experience in taking biosimilars from concept to market across the globe. He is also a patent law practitioner.

Complete Biography